SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001214659-21-008119
Filing Date
2021-08-03
Accepted
2021-08-03 17:26:13
Documents
1
Period of Report
2021-07-30

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-53496.html 3  
1 PRIMARY DOCUMENT marketforms-53496.xml 3 1684
  Complete submission text file 0001214659-21-008119.txt   3061
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address C/O UROGEN PHARMA LTD. 9 HA'TA'ASIYA STREET RA'ANANA L3 4365007
Business Address
Barrett Elizabeth A. (Reporting) CIK: 0001764157 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 211141172